Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics

Leukemia Research

Volumn 38, Issue 6, 2014, Pages 649-659

  Cagnetta, Antonia ^a,b   Adamia, Sophia ^a   Acharya, Chirag ^a   Patrone, Franco ^b   Miglino, Maurizio ^b   Nencioni, Alessio ^b   Gobbi, Marco ^b   Cea, Michele ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

AML; Genomic heterogeneity; Minimal residual disease; Mutations; Prognosis

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ASXL1 GENE; CANCER PROGNOSIS; CEBPA GENE; CYTOGENETICS; DNMT3A GENE; FLT3 GENE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; IDH1 GENE; IDH2 GENE; KARYOTYPE; MLL PTD GENE; NPM1 GENE; PATIENT CODING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RUNX1 GENE; TET2 GENE; WT1 GENE;

AML; GENOMIC HETEROGENEITY; MINIMAL RESIDUAL DISEASE; MUTATIONS; PROGNOSIS;

CCAAT-ENHANCER-BINDING PROTEINS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA-BINDING PROTEINS; FMS-LIKE TYROSINE KINASE 3; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; WT1 PROTEINS;

EID: 84900424984     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.03.006     Document Type: Review

References (174)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Schlenk R.F., Dohner H. Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2013, 2013:324-330.
3. Stone R.M., O'Donnell M.R., Sekeres M.A. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004, 98-117.
4. Riva L., Luzi L., Pelicci P.G. Genomics of acute myeloid leukemia: the next generation. Front Oncol 2012, 2:40.
5. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368:2059-2074.
6. Lo-Coco F., Avvisati G., Vignetti M., Thiede C., Orlando S.M., Iacobelli S., et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Eng J Med 2013, 369:111-121.
7. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
8. Grimwade J.E., Cullinan E.B., Beerman T.A. Neocarzinostatin and auromomycin preferentially cleave simian virus 40 DNA and chromosomes at a number of discrete locations. Biochim Biophys Acta 1988, 950:102-112.
9. Rowley J.D. Chromosomal translocations: revisited yet again. Blood 2008, 112:2183-2189.
10. Mrozek K., Heerema N.A., Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 2004, 18:115-136.
11. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C.J., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
12. Grimwade D., Hills R.K., Moorman A.V., Walker H., Chatters S., Goldstone A.H., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
13. Tefferi A. Prognostic relevance of cytogenetic abnormalities in primary myelofibrosis: comparison of recent reports from Japan, the Mayo Clinic and MD Anderson Cancer Center. Eur J Haematol 2009, 83:290-291.
14. Gregory T.K., Wald D., Chen Y., Vermaat J.M., Xiong Y., Tse W. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol 2009, 2:23.
15. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Eng J Med 2005, 352:254-266.
16. Gaidzik V.I., Bullinger L., Schlenk R.F., Zimmermann A.S., Rock J., Paschka P., et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011, 29:1364-1372.
17. Schlenk R.F., Dohner K., Krauter J., Frohling S., Corbacioglu A., Bullinger L., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Eng J Med 2008, 358:1909-1918.
18. Schnittger S., Kohl T.M., Haferlach T., Kern W., Hiddemann W., Spiekermann K., et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006, 107:1791-1799.
19. Schnittger S., Schoch C., Kern W., Mecucci C., Tschulik C., Martelli M.F., et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005, 106:3733-3739.
20. Pratcorona M., Abbas S., Sanders M.A., Koenders J.E., Kavelaars F.G., Erpelinck-Verschueren C.A., et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica 2012, 97:388-392.
21. Metzeler K.H., Becker H., Maharry K., Radmacher M.D., Kohlschmidt J., Mrozek K., et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011, 118:6920-6929.
22. Taskesen E., Bullinger L., Corbacioglu A., Sanders M.A., Erpelinck C.A., Wouters B.J., et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011, 117:2469-2475.
23. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003, 3:650-665.
24. Patel J.P., Gonen M., Figueroa M.E., Fernandez H., Sun Z., Racevskis J., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Eng J Med 2012, 366:1079-1089.
25. Martelli M.P., Sportoletti P., Tiacci E., Martelli M.F., Falini B. Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev 2013, 27:13-22.
26. Dohner H., Gaidzik V.I. Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program 2011, 2011:36-42.
27. Grossmann V., Schnittger S., Kohlmann A., Eder C., Roller A., Dicker F., et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012, 120:2963-2972.
28. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
29. Grimwade D., Hills R.K. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009, 1:385-395.
30. Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?. Hematology Am Soc Hematol Educ Program 2013, 2013:220-226.
31. Scholl S., Theuer C., Scheble V., Kunert C., Heller A., Mugge L.O., et al. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Eur J Haematol 2008, 80:208-215.
32. Dicker F., Haferlach C., Sundermann J., Wendland N., Weiss T., Kern W., et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010, 24:1528-1532.
33. Marcucci G., Haferlach T., Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011, 29:475-486.
34. Breitenbuecher F., Markova B., Kasper S., Carius B., Stauder T., Bohmer F.D., et al. A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood 2009, 113:4063-4073.
35. Grundler R., Miething C., Thiede C., Peschel C., Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 2005, 105:4792-4799.
36. Choudhary C., Schwable J., Brandts C., Tickenbrock L., Sargin B., Kindler T., et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 2005, 106:265-273.
37. Mrozek K., Marcucci G., Paschka P., Whitman S.P., Bloomfield C.D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification. Blood 2007, 109:431-448.
38. Dohner K., Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008, 93:976-982.
39. Chevallier P., Labopin M., Turlure P., Prebet T., Pigneux A., Hunault M., et al. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia 2011, 25:939-944.
40. DeZern A.E., Sung A., Kim S., Smith B.D., Karp J.E., Gore S.D., et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. J Am Soc Blood Marrow Transplant 2011, 17:1404-1409.
41. Laboure G., Dulucq S., Labopin M., Tabrizi R., Guerin E., Pigneux A., et al. Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD. J Am Soc Blood Marrow Transplant 2012, 18:1845-1850.
42. Paun O., Lazarus H.M. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission: have the indications changed. Curr Opin Hematol 2012, 19:95-101.
43. Sengsayadeth S.M., Jagasia M., Engelhardt B.G., Kassim A., Strickland S.A., Goodman S., et al. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant 2012, 47:1535-1537.
44. How J., Sykes J., Gupta V., Yee K.W., Schimmer A.D., Schuh A.C., et al. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. Cancer 2012, 118:6110-6117.
45. Gale R.E., Green C., Allen C., Mead A.J., Burnett A.K., Hills R.K., et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111:2776-2784.
46. Schnittger S., Bacher U., Kern W., Alpermann T., Haferlach C., Haferlach T. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia 2011, 25:1297-1304.
47. Li W., Zhang L., Huang L., Mi Y., Wang J. Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML. Leuk Res 2012, 36:186-191.
48. Falini B., Martelli M.P. NPM1-mutated AML: targeting by disassembling. Blood 2011, 118:2936-2938.
49. Falini B., Martelli M.P., Bolli N., Sportoletti P., Liso A., Tiacci E., et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity. Blood 2011, 117:1109-1120.
50. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., et al. DNMT3A mutations in acute myeloid leukemia. N Eng J Med 2010, 363:2424-2433.
51. Zhang W., Konopleva M., Shi Y.X., McQueen T., Harris D., Ling X., et al. FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008, 100:184-198.
52. O'Farrell A.M., Foran J.M., Fiedler W., Serve H., Paquette R.L., Cooper M.A., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003, 9:5465-5476.
53. Fathi A., Levis M. FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol 2011, 18:71-76.
54. Grunwald M.R., Levis M.J. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 2013, 97:683-694.
55. Ravandi F., Alattar M.L., Grunwald M.R., Rudek M.A., Rajkhowa T., Richie M.A., et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013, 121:4655-4662.
56. Serve H., Krug U., Wagner R., Sauerland M.C., Heinecke A., Brunnberg U., et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013, 31:3110-3118.
57. Zarrinkar P.P., Gunawardane R.N., Cramer M.D., Gardner M.F., Brigham D., Belli B., et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009, 114:2984-2992.
58. Falini B., Nicoletti I., Bolli N., Martelli M.P., Liso A., Gorello P., et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007, 92:519-532.
59. Liso A., Bogliolo A., Freschi V., Martelli M.P., Pileri S.A., Santodirocco M., et al. In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. Leukemia 2008, 22:1285-1289.
60. Chou W.C., Tang J.L., Lin L.I., Yao M., Tsay W., Chen C.Y., et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006, 66:3310-3316.
61. Falini B., Martelli M.P., Mecucci C., Liso A., Bolli N., Bigerna B., et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica 2008, 93:775-779.
62. Gorello P., Cazzaniga G., Alberti F., Dell'Oro M.G., Gottardi E., Specchia G., et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006, 20:1103-1108.
63. Falini B., Bolli N., Shan J., Martelli M.P., Liso A., Pucciarini A., et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006, 107:4514-4523.
64. Falini B., Bolli N., Liso A., Martelli M.P., Mannucci R., Pileri S., et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 2009, 23:1731-1743.
65. Falini B., Martelli M.P., Bolli N., Bonasso R., Ghia E., Pallotta M.T., et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006, 108:1999-2005.
66. Falini B., Lenze D., Hasserjian R., Coupland S., Jaehne D., Soupir C., et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia 2007, 21:1566-1570.
67. Alcalay M., Tiacci E., Bergomas R., Bigerna B., Venturini E., Minardi S.P., et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 2005, 106:899-902.
68. Verhaak R.G., Goudswaard C.S., van Putten W., Bijl M.A., Sanders M.A., Hugens W., et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005, 106:3747-3754.
69. Becker H., Marcucci G., Maharry K., Radmacher M.D., Mrozek K., Margeson D., et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28:596-604.
70. Garzon R., Garofalo M., Martelli M.P., Briesewitz R., Wang L., Fernandez-Cymering C., et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008, 105:3945-3950.
71. Jongen-Lavrencic M., Sun S.M., Dijkstra M.K., Valk P.J., Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008, 111:5078-5085.
72. Haferlach C., Mecucci C., Schnittger S., Kohlmann A., Mancini M., Cuneo A., et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009, 114:3024-3032.
73. Arber D.A. Realistic pathologic classification of acute myeloid leukemias. Am J Clin Pathol 2001, 115:552-560.
74. Grisendi S., Mecucci C., Falini B., Pandolfi P.P. Nucleophosmin and cancer. Nat Rev Cancer 2006, 6:493-505.
75. Albiero E., Madeo D., Bolli N., Giaretta I., Bona E.D., Martelli M.F., et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia 2007, 21:1099-1103.
76. Bolli N., De Marco M.F., Martelli M.P., Bigerna B., Pucciarini A., Rossi R., et al. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia 2009, 23:501-509.
77. Falini B., Nicoletti I., Martelli M.F., Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007, 109:874-885.
78. Kayser S S.R., Krauter J., et al. Prognostic impact of mutant to wild-type ratio and insertion site in acute myeloid leukemia with FLT3 internal tandem duplication. Blood ASH Annual Meeting Abstracts 2012, 120:785.
79. Cilloni D., Messa F., Rosso V., Arruga F., Defilippi I., Carturan S., et al. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. Leukemia 2008, 22:1234-1240.
80. Röllig C., Bornhauser M., Thiede C., Kramer M., Ho A., Wandt H., et al. Allogenic stem cell transplantation confers a favorable outcome in patients with NPM1 positive acute myeloid leukemia: results from a donor vs. no-donor analysis of 309 patients treated in the SAL AML-2003 trial. Blood 2011, 493. [ASH Annual Meeting Abstracts].
81. Rollig C., Thiede C., Gramatzki M., Aulitzky W., Bodenstein H., Bornhauser M., et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 2010, 116:971-978.
82. Buchner T., Berdel W.E., Haferlach C., Haferlach T., Schnittger S., Muller-Tidow C., et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009, 27:61-69.
83. Timchenko N.A., Harris T.E., Wilde M., Bilyeu T.A., Burgess-Beusse B.L., Finegold M.J., et al. CCAAT/enhancer binding protein alpha regulates p21 protein and hepatocyte proliferation in newborn mice. Mol Cell Biol 1997, 17:7353-7361.
84. Koschmieder S., Halmos B., Levantini E., Tenen D.G. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 2009, 27:619-628.
85. Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001, 27:263-270.
86. Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer 2004, 4:394-400.
87. Wouters B.J., Lowenberg B., Erpelinck-Verschueren C.A., van Putten W.L., Valk P.J., Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009, 113:3088-3091.
88. Wouters B.J., Sanders M.A., Lugthart S., Geertsma-Kleinekoort W.M., van Drunen E., Beverloo H.B., et al. Segmental uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid leukemia. Leukemia 2007, 21:2382-2384.
89. Pabst T., Eyholzer M., Fos J., Mueller B.U. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009, 100:1343-1346.
90. Grossmann V., Haferlach C., Nadarajah N., Fasan A., Weissmann S., Roller A., et al. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76.8% of cases with TET2 and GATA2 alterations impacting prognosis. Br J Haematol 2013, 161:649-658.
91. Fasan A., Haferlach C., Alpermann T., Jeromin S., Grossmann V., Eder C., et al. The role of different genetic subtypes of CEBPA mutated AML. Leukemia 2013, 10.1038/leu.2013.273.
92. Tang J.L., Hou H.A., Chen C.Y., Liu C.Y., Chou W.C., Tseng M.H., et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009, 114:5352-5361.
93. Schnittger S., Dicker F., Kern W., Wendland N., Sundermann J., Alpermann T., et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 2011, 117:2348-2357.
94. Kohlmann A., Nadarajah N., Alpermann T., Grossmann V., Schindela S., Dicker F., et al. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. Leukemia 2014, 28:129-137.
95. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466:1129-1133.
96. Smith A.E., Mohamedali A.M., Kulasekararaj A., Lim Z., Gaken J., Lea N.C., et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010, 116:3923-3932.
97. Mohamedali A.M., Smith A.E., Gaken J., Lea N.C., Mian S.A., Westwood N.B., et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009, 27:4002-4006.
98. Weissmann S., Alpermann T., Grossmann V., Kowarsch A., Nadarajah N., Eder C., et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 2012, 26:934-942.
99. Gaidzik V.I., Paschka P., Spath D., Habdank M., Kohne C.H., Germing U., et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 2012, 30:1350-1357.
100. Gaidzik V.S.R.F., Paschka P., et al. TET2 mutations in acute myeloid leukemia (AML): results on 783 patients treated within the AML HD98A study of the AML Study Group (AMLSG). Blood ASH 2010, abstract # 97:21.
101. Chou W.C., Chou S.C., Liu C.Y., Chen C.Y., Hou H.A., Kuo Y.Y., et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011, 118:3803-3810.
102. Metzeler K.H., Maharry K., Radmacher M.D., Mrozek K., Margeson D., Becker H., et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011, 29:1373-1381.
103. Fernandez H.F., Sun Z., Yao X., Litzow M.R., Luger S.M., Paietta E.M., et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009, 361(September (13)):1249-1259. http://www.ncbi.nlm.nih.gov/pubmed/19776406.
104. Abdel-Wahab O., Manshouri T., Patel J., Harris K., Yao J., Hedvat C., et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010, 70:447-452.
105. Kosmider O., Delabesse E., de Mas V.M., Cornillet-Lefebvre P., Blanchet O., Delmer A., et al. TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. Haematologica 2011, 96:1059-1063.
106. Reitman Z.J., Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010, 102:932-941.
107. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
108. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., et al. IDH1 and IDH2 mutations in gliomas. N Eng J Med 2009, 360:765-773.
109. Tefferi A., Lasho T.L., Abdel-Wahab O., Guglielmelli P., Patel J., Caramazza D., et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010, 24:1302-1309.
110. Green A., Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Eng J Med 2010, 362:369-370.
111. Thol F., Weissinger E.M., Krauter J., Wagner K., Damm F., Wichmann M., et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010, 95:1668-1674.
112. Cairns R.A., Iqbal J., Lemonnier F., Kucuk C., de Leval L., Jais J.P., et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012, 119:1901-1903.
113. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
114. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
115. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
116. Schnittger S., Haferlach C., Ulke M., Alpermann T., Kern W., Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010, 116:5486-5496.
117. Abbas S., Lugthart S., Kavelaars F.G., Schelen A., Koenders J.E., Zeilemaker A., et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 2010, 116:2122-2126.
118. Damm F., Thol F., Hollink I., Zimmermann M., Reinhardt K., van den Heuvel-Eibrink M.M., et al. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia 2011, 25:1704-1710.
119. Paschka P., Schlenk R.F., Gaidzik V.I., Habdank M., Kronke J., Bullinger L., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28:3636-3643.
120. Marcucci G., Maharry K., Wu Y.Z., Radmacher M.D., Mrozek K., Margeson D., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28:2348-2355.
121. Chou W.C., Hou H.A., Chen C.Y., Tang J.L., Yao M., Tsay W., et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010, 115:2749-2754.
122. Patel K.P., Ravandi F., Ma D., Paladugu A., Barkoh B.A., Medeiros L.J., et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 2011, 135:35-45.
123. Hollink I.H., Zwaan C.M., Zimmermann M., Arentsen-Peters T.C., Pieters R., Cloos J., et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 2009, 23:262-270.
124. Boissel N., Nibourel O., Renneville A., Gardin C., Reman O., Contentin N., et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2010, 28:3717-3723.
125. Green C.L., Evans C.M., Zhao L., Hills R.K., Burnett A.K., Linch D.C., et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011, 118:409-412.
126. Thol F., Damm F., Wagner K., Gohring G., Schlegelberger B., Hoelzer D., et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010, 116:614-616.
127. Bestor T.H. The DNA methyltransferases of mammals. Hum Mol Genet 2000, 9:2395-2402.
128. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
129. Chen Z.X., Riggs A.D. Maintenance and regulation of DNA methylation patterns in mammals. Biochem Cell Biol 2005, 83:438-448.
130. Jurkowska R.Z., Jurkowski T.P., Jeltsch A. Structure and function of mammalian DNA methyltransferases. ChemBioChem 2011, 12:206-222.
131. Yamashita Y., Yuan J., Suetake I., Suzuki H., Ishikawa Y., Choi Y.L., et al. Array-based genomic resequencing of human leukemia. Oncogene 2010, 29:3723-3731.
132. Yan X.J., Xu J., Gu Z.H., Pan C.M., Lu G., Shen Y., et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011, 43:309-315.
133. Hou H.A., Kuo Y.Y., Liu C.Y., Chou W.C., Lee M.C., Chen C.Y., et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012, 119:559-568.
134. Gaidzik V.I., Schlenk R.F., Paschka P., Stölzle A., Späth D., et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood 2013, 121(23):4769-4777.
135. Challen G.A., Sun D., Jeong M., Luo M., Jelinek J., Berg J.S., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012, 44:23-31.
136. Li Y., Zhu B. Acute myeloid leukemia with DNMT3A mutations. Leuk Lymphoma 2014, 10.3109/10428194.2013.869802.
137. Thol F., Damm F., Ludeking A., Winschel C., Wagner K., Morgan M., et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011, 29:2889-2896.
138. Zhang Y., Gao Y., Zhang G., Huang S., Dong Z., Kong C., et al. DNMT3a plays a role in switches between doxorubicin-induced senescence and apoptosis of colorectal cancer cells. Int J Cancer 2011, 128:551-561.
139. Fisher C.L., Randazzo F., Humphries R.K., Brock H.W. Characterization of Asxl1, a murine homolog of additional sex combs, and analysis of the Asx-like gene family. Gene 2006, 369:109-118.
140. Cho Y.S., Kim E.J., Park U.H., Sin H.S., Um S.J. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem 2006, 281:17588-17598.
141. Lee S.W., Cho Y.S., Na J.M., Park U.H., Kang M., Kim E.J., et al. ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem 2010, 285:18-29.
142. Wang J., Hevi S., Kurash J.K., Lei H., Gay F., Bajko J., et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet 2009, 41:125-129.
143. An Q., Wright S.L., Konn Z.J., Matheson E., Minto L., Moorman A.V., et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci U S A 2008, 105:17050-17054.
144. Carbuccia N., Murati A., Trouplin V., Brecqueville M., Adelaide J., Rey J., et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009, 23:2183-2186.
145. Gelsi-Boyer V., Trouplin V., Adelaide J., Bonansea J., Cervera N., Carbuccia N., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009, 145:788-800.
146. Gelsi-Boyer V., Trouplin V., Roquain J., Adelaide J., Carbuccia N., Esterni B., et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010, 151:365-375.
147. Carbuccia N., Trouplin V., Gelsi-Boyer V., Murati A., Rocquain J., Adelaide J., et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010, 24:469-473.
148. Boultwood J., Perry J., Pellagatti A., Fernandez-Mercado M., Fernandez-Santamaria C., Calasanz M.J., et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010, 24:1062-1065.
149. Chou W.C., Huang H.H., Hou H.A., Chen C.Y., Tang J.L., Yao M., et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 2010, 116:4086-4094.
150. Thol F., Friesen I., Damm F., Yun H., Weissinger E.M., Krauter J., et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011, 29:2499-2506.
151. Schnittger S., Eder C., Jeromin S., Alpermann T., Fasan A., Grossmann V., et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013, 27:82-91.
152. Balgobind B.V., Zwaan C.M., Pieters R., Van den Heuvel-Eibrink M.M. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia 2011, 25:1239-1248.
153. Caligiuri M.A., Strout M.P., Lawrence D., Arthur D.C., Baer M.R., Yu F., et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 1998, 58:55-59.
154. Dohner K., Tobis K., Ulrich R., Frohling S., Benner A., Schlenk R.F., et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002, 20:3254-3261.
155. Inoue K., Ogawa H., Yamagami T., Soma T., Tani Y., Tatekawa T., et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996, 88:2267-2278.
156. Cilloni D., Gottardi E., De Micheli D., Serra A., Volpe G., Messa F., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002, 16:2115-2121.
157. Cilloni D., Gottardi E., Messa F., Fava M., Scaravaglio P., Bertini M., et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003, 21:1988-1995.
158. Keilholz U., Menssen H.D., Gaiger A., Menke A., Oji Y., Oka Y., et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 2005, 19:1318-1323.
159. Miwa H., Beran M., Saunders G.F. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992, 6:405-409.
160. King-Underwood L., Renshaw J., Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 1996, 87:2171-2179.
161. Cilloni D., Messa F., Arruga F., Defilippi I., Gottardi E., Fava M., et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008, 93:921-924.
162. Inoue K., Sugiyama H., Ogawa H., Nakagawa M., Yamagami T., Miwa H., et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994, 84:3071-3079.
163. Ogawa H., Tamaki H., Ikegame K., Soma T., Kawakami M., Tsuboi A., et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003, 101:1698-1704.
164. Weisser M., Kern W., Rauhut S., Schoch C., Hiddemann W., Haferlach T., et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005, 19:1416-1423.
165. Pozzi S., Geroldi S., Tedone E., Luchetti S., Grasso R., Colombo N., et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol 2013, 160(4):503-509.
166. Schmid D., Heinze G., Linnerth B., Tisljar K., Kusec R., Geissler K., et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997, 11:639-643.
167. Bergmann L., Maurer U., Weidmann E. Wilms tumor gene expression in acute myeloid leukemias. Leukemia Lymphoma 1997, 25:435-443.
168. Barragan E., Cervera J., Bolufer P., Ballester S., Martin G., Fernandez P., et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004, 89:926-933.
169. Noronha S.A., Farrar J.E., Alonzo T.A., Gerbing R.B., Lacayo N.J., Dahl G.V., et al. WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009, 53:1136-1139.
170. Miglino M., Colombo N., Pica G., Grasso R., Clavio M., Bergamaschi M., et al. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leukemia Lymphoma 2011, 52:1961-1969.
171. Paschka P., Marcucci G., Ruppert A.S., Whitman S.P., Mrozek K., Maharry K., et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2008, 26:4595-4602.
172. Virappane P., Gale R., Hills R., Kakkas I., Summers K., Stevens J., et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008, 26:5429-5435.
173. Gaidzik V.I., Schlenk R.F., Moschny S., Becker A., Bullinger L., Corbacioglu A., et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009, 113:4505-4511.
174. Summers K., Stevens J., Kakkas I., Smith M., Smith L.L., Macdougall F., et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 2007, 21:550-551. author reply 552.